Published in Eur J Biochem on April 01, 2003
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
The pathobiology of splicing. J Pathol (2010) 2.52
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res (2008) 2.06
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A (2008) 2.06
DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J (2005) 2.03
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA (2007) 1.78
Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther (2009) 1.76
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm (2009) 1.65
Fluorescent probes for live-cell RNA detection. Annu Rev Biomed Eng (2009) 1.59
Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J Clin Invest (2003) 1.58
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics (2007) 1.43
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res (2003) 1.42
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today (2008) 1.37
Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides (2009) 1.24
Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol (2011) 1.20
Targeted delivery systems for oligonucleotide therapeutics. AAPS J (2009) 1.19
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother (2005) 1.15
RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res (2003) 1.14
The calcium channel alpha2/delta1 subunit is involved in extracellular signalling. J Physiol (2007) 1.11
Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme. Nucleic Acids Res (2007) 1.11
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine (2012) 1.09
Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA. Nucleic Acids Res (2004) 1.08
Inhibition of aac(6')-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria. Proc Natl Acad Sci U S A (2009) 1.08
Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res (2007) 1.06
NMR structure of an alpha-L-LNA:RNA hybrid: structural implications for RNase H recognition. Nucleic Acids Res (2003) 1.06
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio (2008) 1.05
Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release (2008) 1.04
A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res (2007) 1.03
Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA (2009) 1.02
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut (2005) 1.02
External guide sequences targeting the aac(6')-Ib mRNA induce inhibition of amikacin resistance. Antimicrob Agents Chemother (2007) 1.01
Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J (2005) 1.01
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol (2009) 1.01
Metabolic control analysis: a tool for designing strategies to manipulate metabolic pathways. J Biomed Biotechnol (2008) 1.00
Regulation of DNA nucleases by molecular crowding. Nucleic Acids Res (2007) 1.00
Synthesis and physical and physiological properties of 4'-thioRNA: application to post-modification of RNA aptamer toward NF-kappaB. Nucleic Acids Res (2004) 1.00
Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci (2012) 0.99
Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst (2007) 0.99
Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res (2015) 0.99
Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res (2005) 0.98
Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides. Antimicrob Agents Chemother (2003) 0.97
Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology (2008) 0.96
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet (2012) 0.95
Primitive genetic polymers. Cold Spring Harb Perspect Biol (2010) 0.95
A chemical synthesis of LNA-2,6-diaminopurine riboside, and the influence of 2'-O-methyl-2,6-diaminopurine and LNA-2,6-diaminopurine ribosides on the thermodynamic properties of 2'-O-methyl RNA/RNA heteroduplexes. Nucleic Acids Res (2007) 0.95
Antisense-mediated knockdown of Na(V)1.8, but not Na(V)1.9, generates inhibitory effects on complete Freund's adjuvant-induced inflammatory pain in rat. PLoS One (2011) 0.94
Therapeutic regulation of gene expression in the inner ear using RNA interference. Adv Otorhinolaryngol (2009) 0.94
Functionalized 2'-amino-alpha-L-LNA: directed positioning of intercalators for DNA targeting. J Org Chem (2009) 0.93
Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res (2005) 0.92
Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Res (2004) 0.91
Moderate long-term modulation of neuropeptide Y in hypothalamic arcuate nucleus induces energy balance alterations in adult rats. PLoS One (2011) 0.91
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids (2013) 0.91
The pharmacology of HIV drug resistance. Am J Pharm Educ (2006) 0.90
Modulation of RNA splicing as a potential treatment for cancer. Bioeng Bugs (2011) 0.90
Different effects on ACC oxidase gene silencing triggered by RNA interference in transgenic tomato. Plant Cell Rep (2004) 0.89
Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy. RNA Biol (2010) 0.89
Microfluidic methods for production of liposomes. Methods Enzymol (2009) 0.88
Antisense tools for functional studies of human Argonaute proteins. RNA (2010) 0.88
Intra-amygdala injections of CREB antisense impair inhibitory avoidance memory: role of norepinephrine and acetylcholine. Learn Mem (2008) 0.88
Optochemical control of deoxyoligonucleotide function via a nucleobase-caging approach. Acc Chem Res (2013) 0.87
Diels-Alder cycloadditions in water for the straightforward preparation of peptide-oligonucleotide conjugates. Nucleic Acids Res (2006) 0.87
Thermodynamics of RNA duplexes modified with unlocked nucleic acid nucleotides. Nucleic Acids Res (2010) 0.87
Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology (2007) 0.87
Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotechnol (2011) 0.86
A genomic selection strategy to identify accessible and dimerization blocking targets in the 5'-UTR of HIV-1 RNA. Nucleic Acids Res (2004) 0.85
Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids (2013) 0.85
Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur J Pharmacol (2009) 0.85
Reversible site-specific tagging of enzymatically synthesized RNAs using aldehyde-hydrazine chemistry and protease-cleavable linkers. Nucleic Acids Res (2007) 0.85
Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci Rep (2012) 0.85
A versatile method for the preparation of conjugates of peptides with DNA/PNA/analog by employing chemo-selective click reaction in water. Nucleic Acids Res (2007) 0.85
Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res (2004) 0.85
Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA. Nucleic Acids Res (2004) 0.84
Synthesis and properties of 4'-ThioDNA: unexpected RNA-like behavior of 4'-ThioDNA. Nucleic Acids Res (2006) 0.84
Sensitive multiplex PCR assay to differentiate Lyme spirochetes and emerging pathogens Anaplasma phagocytophilum and Babesia microti. BMC Microbiol (2013) 0.84
Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxynucleotides and induction of cytokines. Int J Nanomedicine (2013) 0.84
Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J Gastroenterol (2005) 0.83
Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J Inherit Metab Dis (2010) 0.83
Insights into the DNA stabilizing contributions of a bicyclic cytosine analogue: crystal structures of DNA duplexes containing 7,8-dihydropyrido [2,3-d]pyrimidin-2-one. Nucleic Acids Res (2010) 0.83
Structure and nuclease resistance of 2',4'-constrained 2'-O-methoxyethyl (cMOE) and 2'-O-ethyl (cEt) modified DNAs. Chem Commun (Camb) (2012) 0.83
2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Nucleic Acids Res (2004) 0.82
Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem Biol (2014) 0.82
Antisense oligodeoxynucleotide inhibition as an alternative and convenient method for gene function analysis in pollen tubes. PLoS One (2013) 0.82
Isoenergetic microarrays to study the structure and interactions of DsrA and OxyS RNAs in two- and three-component complexes. Biochemistry (2011) 0.82
Microfluidic assembly of lipid-based oligonucleotide nanoparticles. Anticancer Res (2011) 0.82
Hydroxyproline-based DNA mimics provide an efficient gene silencing in vitro and in vivo. Nucleic Acids Res (2006) 0.82
Twenty years hunting for sulfur in DNA. Protein Cell (2010) 0.82
Structural basis of the RNase H1 activity on stereo regular borano phosphonate DNA/RNA hybrids. Biochemistry (2011) 0.81
Cell-Penetrating Peptides-Mechanisms of Cellular Uptake and Generation of Delivery Systems. Pharmaceuticals (Basel) (2010) 0.81
MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets. Curr Drug Targets (2010) 0.81
Targeted delivery of siRNA. J Biomed Biotechnol (2006) 0.81
Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery. Nucleic Acid Ther (2014) 0.81